Pelabresib + Ruxolitinib for Myelofibrosis

(MANIFEST-3 Trial)

This trial tests whether a new combination of pelabresib and ruxolitinib is more effective than ruxolitinib alone for individuals with certain types of myelofibrosis, a bone marrow disorder. Researchers aim to determine if adding pelabresib, an experimental treatment, improves outcomes for those who have not previously used Janus kinase (JAK) inhibitors. Participants will receive either pelabresib with ruxolitinib or a placebo with ruxolitinib. Suitable candidates have myelofibrosis and have not undergone specific treatments like JAK inhibitors. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.

The trial requires that you stop taking any approved or investigational agents for myelofibrosis, except for hydroxyurea or anagrelide, at least 14 days before starting the study treatment. If you're on other medications, it's best to discuss with the trial team.

Research has shown that the combination of pelabresib and ruxolitinib has been studied for safety and effectiveness. Studies have found that this treatment significantly reduces symptoms like an enlarged spleen and improves conditions such as anemia.

Regarding safety, reports indicate 28 deaths and 22 cases where the disease did not progress in patients using the pelabresib and ruxolitinib combination. Although these numbers might seem concerning, they are similar to those in patients receiving a placebo and ruxolitinib, suggesting that the treatment's safety is comparable to existing options.

Researchers are excited about Pelabresib combined with Ruxolitinib for treating myelofibrosis because it offers a novel approach by targeting the disease differently. While Ruxolitinib, a standard treatment, works by inhibiting certain enzymes to reduce inflammation and symptom burden, Pelabresib adds a new dimension by potentially modifying the underlying disease process through epigenetic modulation. This combination could enhance treatment effectiveness and provide better outcomes for patients who have limited options. Additionally, the possibility of a synergistic effect between Pelabresib and Ruxolitinib might lead to improved symptom management and disease control compared to existing therapies.

Research has shown that combining pelabresib and ruxolitinib holds promise for treating myelofibrosis. One study found that 52.3% of patients experienced a noticeable reduction in symptoms. Additionally, 68% of patients saw at least a 35% decrease in spleen size, a common issue in myelofibrosis. The combination also improved bone marrow structure in 18.8% of patients. In this trial, one group will receive pelabresib with ruxolitinib, while another group will receive a placebo with ruxolitinib. Overall, previous studies have demonstrated that using pelabresib with ruxolitinib is more effective than using ruxolitinib alone.⁶⁷⁸⁹¹⁰